Nuvation Bio's (NUVB) Outperform Rating Reaffirmed at Wedbush

Wedbush reaffirmed their outperform rating on shares of Nuvation Bio (NYSE:NUVB - Free Report) in a research report report published on Monday morning,RTT News reports. They currently have a $5.00 price objective on the stock. Wedbush also issued estimates for Nuvation Bio's Q3 2025 earnings at ($0.17) EPS, Q4 2025 earnings at ($0.19) EPS, FY2025 earnings at ($0.62) EPS, FY2026 earnings at ($0.73) EPS and FY2027 earnings at ($0.48) EPS.

Several other brokerages have also recently issued reports on NUVB. Royal Bank of Canada restated an "outperform" rating and issued a $10.00 price target (up previously from $6.00) on shares of Nuvation Bio in a research report on Tuesday, January 7th. HC Wainwright boosted their target price on shares of Nuvation Bio from $10.00 to $11.00 and gave the company a "buy" rating in a research note on Thursday, January 23rd. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Nuvation Bio currently has an average rating of "Buy" and an average target price of $8.20.

Nuvation Bio Trading Up 7.7 %

Nuvation Bio stock traded up $0.15 during trading on Monday, hitting $2.04. The company had a trading volume of 2,725,517 shares, compared to its average volume of 2,474,208. The company's 50 day simple moving average is $2.42 and its 200-day simple moving average is $2.59. Nuvation Bio has a 1-year low of $1.67 and a 1-year high of $4.16. The stock has a market cap of $684.91 million, a price-to-earnings ratio of -0.94 and a beta of 1.47.

Remove Ads

Hedge Funds Weigh In On Nuvation Bio

Several institutional investors and hedge funds have recently added to or reduced their stakes in NUVB. State Street Corp increased its stake in shares of Nuvation Bio by 4.8% in the third quarter. State Street Corp now owns 4,166,441 shares of the company's stock worth $9,541,000 after acquiring an additional 191,031 shares during the last quarter. Wellington Management Group LLP grew its stake in shares of Nuvation Bio by 83.3% in the 3rd quarter. Wellington Management Group LLP now owns 623,973 shares of the company's stock valued at $1,429,000 after buying an additional 283,642 shares in the last quarter. Geode Capital Management LLC increased its holdings in Nuvation Bio by 5.1% in the third quarter. Geode Capital Management LLC now owns 4,028,692 shares of the company's stock worth $9,227,000 after buying an additional 196,247 shares during the last quarter. JPMorgan Chase & Co. grew its position in Nuvation Bio by 479.1% in the third quarter. JPMorgan Chase & Co. now owns 442,913 shares of the company's stock worth $1,014,000 after acquiring an additional 366,429 shares in the last quarter. Finally, Point72 Asset Management L.P. bought a new position in shares of Nuvation Bio during the 3rd quarter valued at $634,000. 61.67% of the stock is currently owned by hedge funds and other institutional investors.

Nuvation Bio Company Profile

Nuvation Bio Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer.